Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil

Objective: To address that, despite widespread use of ChAdOx1 nCoV-19 (AZD1222) as a COVID-2019 booster, fourth-dose clinical outcomes data are limited. We report immunogenicity and safety for ChAdOx1 nCoV-19 as a homologous fourth-dose booster. Participants and Methods: Participants (aged ≥18 years...

Full description

Saved in:
Bibliographic Details
Main Authors: Sue Ann Costa Clemens, MD, PhD, Sagida Bibi, PhD, Natalie G. Marchevsky, MSc, Parvinder K. Aley, PhD, Federica Cappuccini, PhD, Sophie A. Davies, BSc, Isabela Gonzalez, PhD, Sarah C. Kelly, MSc, Yama F. Mujadidi, MSc, Eveline Pipolo Milan, MD, PhD, Alexandre V. Schwarzbold, PhD, Eduardo Sprinz, MD, DSc, Merryn Voysey, DPhil, Lily Y. Weckx, MD, PhD, Daniel Wright, DPhil, Himanshu Bansal, MS, Maria A.S. Bergagård, MSc, Abby J. Isaacs, MS, Elizabeth J. Kelly, PhD, Dongmei Lan, MS, Shethah Morgan, PhD, Nirmal Kumar Shankar, BAMS, Kathryn Shoemaker, MS, Tonya L. Villafana, PhD, Teresa Lambe, PhD, Justin A. Green, MD, PhD, Andrew J. Pollard, FMedSci
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2542454825000530
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2542454825000530

Similar Items